Clinical Trials
4
Active:1
Completed:1
Trial Phases
2 Phases
Phase 1:2
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (50.0%)Phase 2
2 (50.0%)Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
Phase 1
Recruiting
- Conditions
- Multiple Sclerosis (MS)Parkinson Disease (PD)Amyotrophic Lateral Sclerosis (ALS)Alzheimer Disease (AD)
- Interventions
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Ashvattha Therapeutics, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT05395624
- Locations
- 🇺🇸
UCSF, San Francisco, California, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸Mayo Clinic Jacksonville, Jacksonville, Florida, United States
Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME
Phase 2
Active, not recruiting
- Conditions
- Neovascular Age-related Macular DegenerationDiabetic Macular Edema
- Interventions
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Ashvattha Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT05387837
- Locations
- 🇺🇸
Macro Trials, Los Angeles, California, United States
🇺🇸University Retina - Lemont, Lemont, Illinois, United States
🇺🇸Midwest Eye Institute - North, Indianapolis, Indiana, United States
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy Participants
Phase 1
Completed
- Conditions
- Diabetic Macular EdemaNeovascular Age-related Macular Degeneration
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Ashvattha Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT05105607
- Locations
- 🇦🇺
Nucleus Network (Brisbane), Brisbane, Queensland, Australia
A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- Ashvattha Therapeutics, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT04458298
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
🇺🇸Research site, Baltimore, Maryland, United States
News
No news found